Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines.
AffiliationImmunology Group, Paterson Institute for Cancer Research, The University of Manchester, Manchester
MetadataShow full item record
AbstractPseudomyxoma peritonei (PMP) is a rare tumor of appendiceal origin. Treatment is major cytoreductive surgery but morbidity is high. PMP is considered chemo-resistant; its molecular biology is understudied; and presently, there is no platform for pre-clinical drug testing. Here, we performed exon array analysis from laser micro-dissected PMP tissue and normal colonic epithelia. The array analysis identified 27 up-regulated and 34 down-regulated genes: candidate up-regulated genes included SLC16A4, DSC3, Aldolase B, EPHX4, and ARHGAP24; candidate down-regulated genes were MS4A12, TMIGD1 and Caspase-5. We confirmed differential expression of the candidate genes and their protein products using in-situ hybridization and immuno-histochemistry. In parallel, we established two primary PMP cell lines, N14A and N15A, and immortalized with an SV40 T-antigen lentiviral vector. We cross-checked for expression of the candidate genes (from the array analyses) using qPCR in the cell lines and demonstrated that the gene profiles were distinct from those of colorectal tumor libraries and commonly used colon cell lines. N14A and N15A were responsiveness to mitomycin and oxaliplatin. This study characterizes global gene expression in PMP, and the parallel development of the first immortalized PMP cell lines; fit for pre-clinical testing and PMP oncogene discovery.
CitationGlobal gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines. 2015: Oncotarget
- Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
- Authors: Gleeson EM, Feldman R, Mapow BL, Mackovick LT, Ward KM, Morano WF, Rubin RR, Bowne WB
- Issue date: 2018 Aug
- MUC2 is a molecular marker for pseudomyxoma peritonei.
- Authors: O'Connell JT, Hacker CM, Barsky SH
- Issue date: 2002 Sep
- Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
- Authors: Bjersand K, Mahteme H, Sundström Poromaa I, Andréasson H, Graf W, Larsson R, Nygren P
- Issue date: 2015 Dec
- Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
- Authors: Yan F, Lin Y, Zhou Q, Chang H, Li Y
- Issue date: 2020 Mar
- GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
- Authors: Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Niger M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, de Braud F
- Issue date: 2016 May 6